Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables - Net (2016 - 2019)

Historic Receivables - Net for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2019 value amounting to $87000.0.

  • Theravance Biopharma's Receivables - Net fell 9712.3% to $87000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $87000.0, marking a year-over-year decrease of 9712.3%. This contributed to the annual value of $620000.0 for FY2018, which is 7248.11% down from last year.
  • According to the latest figures from Q3 2019, Theravance Biopharma's Receivables - Net is $87000.0, which was down 9712.3% from $111000.0 recorded in Q2 2019.
  • Theravance Biopharma's 5-year Receivables - Net high stood at $3.4 million for Q2 2018, and its period low was $87000.0 during Q3 2019.
  • Moreover, its 5-year median value for Receivables - Net was $1.2 million (2017), whereas its average is $1.3 million.
  • Per our database at Business Quant, Theravance Biopharma's Receivables - Net skyrocketed by 1873333.33% in 2015 and then crashed by 9712.3% in 2019.
  • Quarter analysis of 5 years shows Theravance Biopharma's Receivables - Net stood at $1.9 million in 2015, then crashed by 66.39% to $646000.0 in 2016, then skyrocketed by 248.76% to $2.3 million in 2017, then plummeted by 72.48% to $620000.0 in 2018, then plummeted by 85.97% to $87000.0 in 2019.
  • Its Receivables - Net stands at $87000.0 for Q3 2019, versus $111000.0 for Q2 2019 and $113000.0 for Q1 2019.